Given that the monoclonal proliferation of tumor B cells would compromise the repertoire of activated B cells entering the circulation, we hypothesized that the impact of malignant B cells might be imprinted in the clonal diversity of the BCR IR in the post-ASCR therapy. This evidence concerns the gene BCR and neoplasm.